ARTICLE | Company News
Novartis, PDL BioPharma deal
May 30, 2016 7:00 AM UTC
Novartis granted newly launched PDL subsidiary, Noden Pharma DAC, exclusive, worldwide commercialization rights to aliskiren to treat hypertension. Novartis will receive $110 million up front and $89 ...